共 395 条
[31]
Schuster SJ(2020)Preliminary results of Balli-01: a phase I study of UCART22 (allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor) in adult patients with relapsed or refractory (R/R) CD22+ B-cell acute lymphoblastic leukemia (B-ALL) Blood 11 31-154
[32]
Bishop MR(2020)Ameli-01: Phase I, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART123 (allogeneic engineered T-cells expressing anti-CD123 chimeric antigen receptor), administered in patients with relapsed/refractory acute myeloid leukemia Blood 41 2503-1157
[33]
Tam CS(2021)Outlook for new CAR-based therapies with a focus on CAR NK cells: what lies beyond CAR-engineered T cells in the race against cancer Cancer Discov 9 27797-1575
[34]
Waller EK(2020)Engineering NK cells for CAR therapy-recent advances in gene transfer methodology Front Immunol 9 136-508
[35]
Borchmann P(2000)Efficient generation of stably electrotransfected human hematopoietic cell lines without drug selection by consecutive FAC sorting Cytometry 5 985-412
[36]
McGuirk JP(2018)Efficient and non-genotoxic RNA-based engineering of human T cells using tumor-specific T cell receptors with minimal TCR mispairing Front Immunol 16 86359-758
[37]
Wang M(2018)A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches Oncotarget 34 25-3260
[38]
Munoz J(2021)Bone marrow mesenchymal stromal cell-mediated resistance in multiple myeloma against NK cells can be overcome by introduction of CD38-CAR or TRAIL-variant Hemasphere 7 300060519893496-1644
[39]
Goy A(2019)Optimizing CAR-T Cell manufacturing processes during pivotal clinical trials Mol Ther Methods Clin Dev 67 281-965
[40]
Locke FL(2020)B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches Leukemia 48 146-1259